Cargando…

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents. Identification of predictive biomarkers is highly needed to optimize patient care. Circulating mar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montemagno, Christopher, Hagege, Anais, Borchiellini, Delphine, Thamphya, Brice, Rastoin, Olivia, Ambrosetti, Damien, Iovanna, Juan, Rioux-Leclercq, Nathalie, Porta, Camillio, Negrier, Sylvie, Ferrero, Jean-Marc, Chamorey, Emmanuel, Pagès, Gilles, Dufies, Maeva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714499/ https://www.ncbi.nlm.nih.gov/pubmed/33299657 http://dx.doi.org/10.1080/2162402X.2020.1846901

Ejemplares similares

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma
por: Ambrosetti, Damien, et al.
Publicado: (2018)

A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2023)

The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
por: Hagege, Anais, et al.
Publicado: (2021)

Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
por: Hagege, Anais, et al.
Publicado: (2022)

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2021)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
por: Giuliano, Sandy, et al.
Publicado: (2019)

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma
por: Polena, Helena, et al.
Publicado: (2018)

Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients
por: Fabbri, Lucilla, et al.
Publicado: (2020)

New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
por: Dufies, Maeva, et al.
Publicado: (2019)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

SH3BGRL2, a new downregulated tumor suppressor in clear cell renal cell carcinomas
por: Dufies, Maeva
Publicado: (2020)

VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
por: Ndiaye, Papa Diogop, et al.
Publicado: (2019)

TFE3‐PD‐L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma
por: Guo, Xudong, et al.
Publicado: (2020)

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
por: Li, Hui, et al.
Publicado: (2020)

New Phenylspirodrimanes from the Sponge-Associated Fungus Stachybotrys chartarum MUT 3308
por: Dayras, Marie, et al.
Publicado: (2023)

PK/PD modeling based on NO-ET homeostasis for improving management of sunitinib-induced hypertension in rats
por: Liu, Hao-chen, et al.
Publicado: (2020)

In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
por: Montemagno, Christopher, et al.
Publicado: (2021)

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model
por: Rayman, Patricia, et al.
Publicado: (2015)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
por: Perrichet, Anaïs, et al.
Publicado: (2020)

Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
por: Cooley, Lindsay S., et al.
Publicado: (2021)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders
por: Windyga, Jerzy, et al.
Publicado: (2022)

Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Buonerba, Carlo, et al.
Publicado: (2020)

LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes
por: Jing, Lun, et al.
Publicado: (2019)

RRM2 Regulates Sensitivity to Sunitinib and PD‐1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway
por: Xiong, Wei, et al.
Publicado: (2021)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
por: Schindler, E, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Sunitinib re-challenge in advanced renal-cell carcinoma
por: Porta, C, et al.
Publicado: (2014)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
por: Bialek, Joanna, et al.
Publicado: (2022)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
por: Manson, Guillaume, et al.
Publicado: (2020)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kuj9cits62kmtjc9lh1up4rnec